Biotech: Page 49
-
PharmaVoice Team/PharmaVoice
John T. Spitznagel — A New Horizon
PharmaVOICE EARLY ON IN HIS CAREER,JOHN SPITZNAGEL SET HIS SIGHTS ON ONE DAY RUNNING A HEALTHCARE COMPANY. IN MAY 2002, AS CHAIRMAN AND CEO OF ESP PHARMA, HIS VISION BECAMEAREALITYONCEAGAIN. Mr. Spitznagel already has proven that he has what it takes to drive a company to success, having engineer...
By Kim Ribbink • Jan. 11, 2010 -
PharmaVoice Team/PharmaVoice
Contents
In Every Issue 3 Letter from the Editor 8 Upfront A brief review of industry news at press time 36 Pharma Trax Sales, marketing, and R&D trends from industry analysts 40 What’s New New healthcare-related products, services, and companies 42 E-Media New electronic and Web-based applications, s...
By PharmaVoice Team • Dec. 28, 2009 -
Explore the Trendline➔
Getty Images
TrendlineOncology R&D
Cancer research remains a prime focus for the industry and often leads to pharma’s most impactful breakthroughs.
By PharmaVoice staff -
PharmaVoice Team/PharmaVoice
Partners in Public Health
The first influenza pandemic of the 21st century is under way. H1N1 influenza A has affected more than 207 countries and overseas territories worldwide, according the World Health Organization. As of the end of November 2009, 622,482 cases have been reported, including more than 7,820 deaths. In ...
By Denise Myshko • Dec. 28, 2009 -
PharmaVoice Team/PharmaVoice
Executive Coaching
The goal of coaching is the goal of good management: and that is to make the most of an organization’s valuable resources — Harvard Business Review he International Coach Federation (ICF), one of the largest worldwide resources for professional coaches, defines coaching as partnering with clien...
By Taren Grom • Dec. 28, 2009 -
PharmaVoice Team/PharmaVoice
Dr. Thomas Steitz: The Right Chemistry
Brilliance begets brilliance, and from early in his career, Thomas Steitz, Ph.D., has learned from and kept company with some of the most highly lauded scientific minds of the 20th and 21st centuries. Over the years, breakthrough discoveries regarding the ribosome have led to Dr. Steitz being oft...
By Kim Ribbink • Dec. 28, 2009 -
PharmaVoice Team/PharmaVoice
Talent Pool
Biotechnology POOL Dr. Diane JORKASKY Aileron Therapeutics Appoints Medical Chief Aileron Therapeutics, a biotechnology company discovering and developing a novel class of therapeutics called stapled peptides, has appointed Diane Jorkasky, M.D., senior VP, head of development and chief medical of...
By PharmaVoice Team • Dec. 28, 2009 -
PharmaVoice Team/PharmaVoice
What's New
Oncology Performance Edge, Health Strategies Group’s recently launched strategic research service, helps marketing and sales executives in the oncology field improve brand performance by understanding how best to invest their resources. “The oncology market is significantly different from others,...
By PharmaVoice Team • Dec. 28, 2009 -
PharmaVoice Team/PharmaVoice
The Year Ahead
Looking back to the varying changes and pressures the industry has endured, and ahead to how the industry will need to reinvent itself to continue to prosper, companies are adapting to longer-term marketplace trends and evolving patient needs. The industry is facing pressure from the economic, re...
By Denise Myshko and Robin Robinson • Nov. 10, 2009 -
PharmaVoice Team/PharmaVoice
The Safety First Era
The classwide requirement for Risk Evaluation and Mitigation Strategies (REMS) for opioid products is likely to have a profound impact on the pharmaceutical industry and healthcare. While most REMS involve only a medication guide — which is likely to have little impact on the prescribing process ...
By PharmaVoice Team • Nov. 10, 2009 -
PharmaVoice Team/PharmaVoice
RNAI Technology
Coming of Age: RNAi Technology As advances in genetics continue to improve our understanding of disease, RNAi will have the opportunity to create entirely new classes of medicines. Researchers say RNA-based therapeutic technology will have a tremendous impact on pharmaceutical research in the n...
By Denise Myshko • Nov. 10, 2009 -
PharmaVoice Team/PharmaVoice
The Innovation Challenge
There has been a great deal of discussion related to the challenges hampering innovation to create differentiated medicines. Never before have research and cutting-edge science been more important to ensure a steady flow of innovation. Much has been made of the industry’s decline in R&D pro...
By PharmaVoice Team • Nov. 10, 2009 -
PharmaVoice Team/PharmaVoice
The Executive Suite
Meeting challenges head-on David E. I. Pyott, CBE Chairman of the Board and CEO Allergan Inc. Allergan draws stability, strength, and value from its growth equation — a business model that balances diverse specialties with a focused approach and a leadership presence in markets around the globe. ...
By PharmaVoice Team • Nov. 10, 2009 -
PharmaVoice Team/PharmaVoice
Talent Pool
Pharmaceutical POOL Stanley BARSHAY Dr. Richard BOWLES Richard CLARK Willie DEESE Kenneth FRAZIER Dr. Peter KIM Raul KOHAN Merck Unveils Post-Merger Organizational Structure Merck has announced its new organizational structure following the completion of its merger with Schering-Plough. The new M...
By PharmaVoice Team • Nov. 10, 2009 -
PharmaVoice Team/PharmaVoice
On the Calendar
November 16-17 Pharmaceutical Coverage & Reimbursement Conference Washington, D.C. Q1 Productions, q1productions.com November 16-17 The 3rd Pediatric Clinical Trials Grand Hyatt Washington, Washington, D.C. ExL Pharma, exlpharma.com November 17-18, 2009 13th Advanced Forum on Structuring, Neg...
By PharmaVoice Team • Nov. 9, 2009 -
PharmaVoice Team/PharmaVoice
Index
Julian Adams, Ph.D. President, Research and Development and Chief Scientific Officer, Infinity Pharmaceuticals Inc. Brent Ahrens. General Partner, Canaan Partners Kenneth C. Aldrich. CEO, Chairman, and Co-Founder, International Stem Cell Corp. Meryl Allison. Principal, Deloitte Consulting Karl...
By PharmaVoice Team • Nov. 9, 2009 -
PharmaVoice Team/PharmaVoice
What's New
inVentiv Health’s recently launched risk evaluation and mitigation strategy (REMS) offering provides pharmaceutical and biotechnology clients with a customizable suite of REMS-related services that can be delivered through a single, integrated program. In an effort to assure safe use of prescript...
By PharmaVoice Team • Nov. 9, 2009 -
PharmaVoice Team/PharmaVoice
UpFront
In Memoriam Linda Ley Ciccarelli Linda Ciccarelli, VP and senior director of media services at Sudler & Hennessey, passed away on Sunday, Sept. 27, 2009, at her home in Wakefield, R.I. A founding member of the Association of Healthcare Media Directors (AHMD), Ms. Ciccarelli was a longtime lea...
By PharmaVoice Team • Nov. 9, 2009 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
2010 — Time to Move Forward The consensus is pretty clear: 2009 is best left behind. People began writing off this year back in June and started setting their sights on first-quarter 2010. Fiscal projections aside, this Gregorian leapfrog of the calendar was more of a mindset throughout the indus...
By Taren Grom • Nov. 9, 2009 -
PharmaVoice Team/PharmaVoice
Felix Theeuwes — Durect Results
Results With more than 30 years experience in developing innovative drugdelivery technologies, Dr.Felix Theeuwes as chairman and chief scientific officer of Durect, is directing the startup company with the goal of commercializing pharmaceutical systems that . BY KIM RIBBINK Photos: Scott Lewis C...
By PharmaVoice Team • Nov. 4, 2009 -
PharmaVoice Team/PharmaVoice
Biotech Clusters
held in Toronto in June, drew exhibitors from 28 countries and 47 U.S. states many of whom were in attendance to unveil their region’s assets as biotechnology centers of excellence. The message being delivered was biotech “cluster.” State and city officials were eager to reach out to the 15,000 p...
By Alex Robinson and Taren Grom • Nov. 4, 2009 -
PharmaVoice Team/PharmaVoice
Animal Farm — The Promise of Xenotransplantation
Animal Farm BY DENISE MYSHKO NO ONE WOULD DISPUTE THAT THERE IS A SHORTAGE OF HEARTS, KIDNEYS, OR LIVERS FOR THOSE WHO REQUIRE A NEW ONE. Last year in the United States alone, 6,000 people died while awaiting an organ transplant. Campaigns to increase organ donation have been somewhat successful ...
By PharmaVoice Team • Nov. 4, 2009 -
PharmaVoice Team/PharmaVoice
Talent Pool
Pharma POOL Andrew R.J. BONFIELD Bristol Myers Squibb Appoints New Senior VP and Chief Financial Officer Andrew R.J. Bonfield joins Bristol Myers Squibb as senior VP and chief financial officer. Mr. Bonfield, 39, served most recently as executive director of finance at BGGroup Plc., a multibillio...
By PharmaVoice Team • Nov. 3, 2009 -
PharmaVoice Team/PharmaVoice
E-Media
NEW ELECTRONIC AND WEBBASED APPLICATIONS, SITES, AND TECHNOLOGIES West Pharmaceutical Services Inc. has launched eWestDirect.com, the industry’s first ecommerce enabled Website focused on supporting cus tomers with online technical guidance,as well as a source for buying pharma ceutical closures....
By PharmaVoice Team • Nov. 3, 2009 -
PharmaVoice Team/PharmaVoice
CROs: Mission Possible
MISSION ANALYSTS … JOSEPH AVELLONE,M.D. President and CEO,Veritas Medicine Inc., Cambridge, Mass.;Veritas Medicine is a leading provider of Internet and patientdatabase services to identify and recruit patients into appropriate clinical trials ALFRED G.CHILDERS,PH.D. Principal and president of ad...
By PharmaVoice Team • Nov. 2, 2009 -
PharmaVoice Team/PharmaVoice
Debby Jo Blank — Point-Blank
“IT’S NOT AS HARD AS IT SOUNDS,” Dr. Blank responds when asked how she juggles the myriad tasks assigned to her as chief business officer of healthcare and agriculture at Genencor International Inc. “Genencor has an objectivesetting process every year and we run the company by organizing our acti...
By Kim Ribbink • Nov. 2, 2009
Previous
